![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
G Bonanno and M Raiteri
Istituto di Farmacologia e Farmacognosia, Universita degli Studi di Genova, Italy.
The aim of this work was the identification of pharmacologically distinct subtypes of gamma-aminobutyric acidB (GABAB) receptors in the central nervous system. Inasmuch as GABAB receptors are often sited on axon terminals where they mediate inhibition of transmitter release, we chose as models the GABAB receptors mediating inhibition of release of 1) endogenous GABA; 2) endogenous glutamate; and 3) somatostatin-like immunoreactivity (SRIF-LI). The experimental set up consisted of rat cerebrocortical synaptosomes depolarized in superfusion with 12 or 15 mM KCl. Endogenous GABA and glutamate were measured by high-performance liquid chromatography and SRIF-LI by radioimmunoassay. The selective GABAB receptor agonist (-)-baclofen inhibited in a concentration- dependent manner the K(+)-evoked release of GABA, glutamate and SRIF-Ll with similar potencies and efficacies [EC50 values, 1.1-1.5 microM; maximal inhibition, 45-50% at about 10 microM (-)-baclofen]. The GABAB receptor antagonist phaclofen concentration-dependently reduced the effects of (-)-baclofen on the release of GABA and SRIF-Ll but not on the release of glutamate, where it was ineffective up to 1000 microM. The rank order of potency (Ki values are shown in parentheses) are: SRIF-Ll (7.8 microM); GABA (10.4 microM); and glutamate (greater than 115 microM). The novel GABAB receptor antagonist 3- aminopropyl(diethoxymethyl) phosphinic acid (CGP 35348) displayed a different pattern on the three release systems examined (Ki values are shown in parentheses): SRIF-Ll (0.38 microM); glutamate (0.48 microM); and endogenous GABA (greater than 115 microM).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  M. Raiteri Functional pharmacology in human brain. Pharmacol. Rev., June 1, 2006; 58(2): 162 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. Carter, A. W. Unzeitig, H. Wu, W. Chen, A. Coop, W. Koek, and C. P. France The Discriminative Stimulus Effects of {gamma}-Hydroxybutyrate and Related Compounds in Rats Discriminating Baclofen or Diazepam: The Role of GABAB and GABAA Receptors J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Bowery, B. Bettler, W. Froestl, J. P. Gallagher, F. Marshall, M. Raiteri, T. I. Bonner, and S. J. Enna International Union of Pharmacology. XXXIII. Mammalian gamma -Aminobutyric AcidB Receptors: Structure and Function Pharmacol. Rev., June 1, 2002; 54(2): 247 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Enna A GABAB Mystery: The Search for Pharmacologically Distinct GABAB Receptors Mol. Interv., October 1, 2001; 1(4): 208 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gutovitz, J. T. Birmingham, J. A. Luther, D. J. Simon, and E. Marder GABA Enhances Transmission at an Excitatory Glutamatergic Synapse J. Neurosci., August 15, 2001; 21(16): 5935 - 5943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamada, B. Yu, and J. P. Gallagher Different Subtypes of GABAB Receptors Are Present at Pre- and Postsynaptic Sites Within the Rat Dorsolateral Septal Nucleus J Neurophysiol, June 1, 1999; 81(6): 2875 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Dittman and W. G. Regehr Mechanism and Kinetics of Heterosynaptic Depression at a Cerebellar Synapse J. Neurosci., December 1, 1997; 17(23): 9048 - 9059. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
